Atlas Trials

Metastatic Ovarian Carcinoma

20 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Metastatic Ovarian Carcinoma

RecordFirmDate
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373)M.D. Anderson Cancer Center2022-04-29
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484)National Cancer Institute (NCI)2021-11-22
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (NCT05075993)M.D. Anderson Cancer Center2021-11-12
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448)University of Washington2021-10-18
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (NCT04811703)Hospices Civils de Lyon2021-07-30
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494)National Cancer Institute (NCI)2021-04-26
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520)Pamela Munster2021-03-31
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (NCT04703920)University of Michigan Rogel Cancer Center2021-03-04
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555)Wake Forest University Health Sciences2019-11-11
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (NCT03610490)M.D. Anderson Cancer Center2018-10-16
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986)Roswell Park Cancer Institute2017-07-14
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02627443)National Cancer Institute (NCI)2017-05-16
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959)National Cancer Institute (NCI)2015-04-08

Track Metastatic Ovarian Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.